BMY

Phil M. Holzer

Known title: SVP and ControllerCIK: 0002012588

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Bristol Myers Squibb sees mixed trial results and dividend focus. Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.

this person other insiders at BMY

Transaction History

BMY▼ Sell$34K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$16K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$15K
BMY▲ Buy$0
BMY▼ Sell$51K
BMY▼ Sell$0
BMY▼ Sell$0
BMY▼ Sell$15K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$15K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$70K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$15K
BMY▲ Buy$0
BMY▼ Sell$39K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$10K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$11K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$53K

We use analytics to understand how market-wall is used. No personal data is sold.